NABILONE-DEA SCHEDULE II
- CAS No.
- 51022-71-0
- Chemical Name:
- NABILONE-DEA SCHEDULE II
- Synonyms
- Nabilone;lilly109514;Nabilone solution;trans-(+-)-hydroxy-;NABILONE-DEA SCHEDULE II;d)pyran-9-one,3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-9h-dibenzo(;(6aR,10aR)-1-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-6,6a,7,8,10,10a-hexahydrobenzo[c]chromen-9-one;trans-6,6-Dimethyl-3-(1,1-dimethylheptyl)-1-hydroxy-6,6a,7,8,10,10a-hexahydro-9H-dibenzo[b,d]pyran-9-one;9H-Dibenzo[b,d]pyran-9-one, 3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-, (6aR,10aR)-rel-;NabiloneQ: What is Nabilone Q: What is the CAS Number of Nabilone Q: What is the storage condition of Nabilone Q: What are the applications of Nabilone
- CBNumber:
- CB4504001
- Molecular Formula:
- C24H36O3
- Molecular Weight:
- 372.54
- MOL File:
- 51022-71-0.mol
- Modify Date:
- 2023/5/29 13:57:48
SAFETY
Risk and Safety Statements
| Symbol(GHS) |   GHS07,GHS08 |
|---|---|
| Signal word | Warning |
| Hazard statements | H302-H336-H361 |
| Precautionary statements | P202-P261-P264-P270-P301+P312-P308+P313 |
| Hazard Codes | Xn,F |
| Risk Statements | 22-36-20/21/22-11 |
| Safety Statements | 36/37/39-45-36/37-16 |
| WGK Germany | 3 |
| RTECS | HP8756000 |
| DEA Controlled Substances | CSCN: 7379 CAS SCH: II NARC: N |
NABILONE-DEA SCHEDULE II Chemical Properties,Uses,Production
Chemical Properties
White to Off-White Solid
Uses
A labelled synthetic cannabinoid with antiemetic, antiglaucoma, and CNS activity. Antiemetic. Controlled substance (hallucinogen).
World Health Organization (WHO)
Nabilone is a structural analogue of dronabinol (delta-9- tetrahydrocannabinol), the major active component of cannabis.
Pharmacology
Nabilone is a synthetic analogue of THC that has shown particular promise in laboratory models of CUD. Nabilone has better bioavailability, a longer duration of action, and lower abuse liability than dronabinol, and since it produces unique urinary metabolites, researchers can distinguish cannabis use from medication compliance. Haney et al. investigated two doses of nabilone in the human laboratory and showed that this medication significantly decreased a laboratory measure of cannabis relapse and improved mood symptoms of withdrawal, such as irritability. Further, the higher nabilone dose also decreased craving for cannabis, increased quality of sleep, and improved food intake. In 2016, Herrmann et al. used a similar human laboratory design to test the combination of nabilone and the GABAA agonist, zolpidem, hypothesizing that combining nabilone with an efficacious sleep medication may produce more robust reductions in cannabis withdrawal and relapse than those observed with nabilone alone by Haney et al. Zolpidem was also tested alone, and although it improved sleep during cannabis withdrawal relative to placebo, it did not reduce relapse. The combination of zolpidem and nabilone provided a more comprehensive reduction in withdrawal symptoms (negative mood, anorexia, disrupted sleep) and also reduced cannabis relapse. The authors suggest that the majority of these effects are attributable to nabilone. These laboratory findings await confirmation in clinical treatment settings, but the results of these studies demonstrate that nabilone holds considerable promise for CUD treatment.